Development of the Extended Infusion Set and Its Mechanism of Action

Gina Zhang, Ohad Cohen, Sarnath Chattaraj*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

Continuous subcutaneous insulin infusion (CSII, or insulin pump) and continuous glucose monitoring (CGM) sensors have been increasingly used and associated with improved glycemic control by people with type 1 diabetes and insulin-requiring type 2 diabetes. Commonly used infusion sets in most CSII systems are limited to a wear time of 3 days. In contradistinction, CGM sensors are currently approved for seven and more days of wear. With the motivation to provide a 7-day infusion set that matches the CGM wear time and to improve patient experience, the recently CE-marked and FDA 510k–cleared Medtronic extended infusion set (EIS) was designed.s The EIS offers enhanced new features that include use for up to 7 days, improved convenience, comfort, and better quality of life for insulin pump users.

Original languageEnglish
Pages (from-to)454-459
Number of pages6
JournalJournal of diabetes science and technology
Volume18
Issue number2
DOIs
StatePublished - Mar 2024
Externally publishedYes

Funding

FundersFunder number
Medtronic

    Keywords

    • CSII
    • extended wear
    • insulin infusion set
    • unexplained hyperglycemia

    Fingerprint

    Dive into the research topics of 'Development of the Extended Infusion Set and Its Mechanism of Action'. Together they form a unique fingerprint.

    Cite this